Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy

Area of Science:

• Oncology
• Immunotherapy
• Renal Cell Carcinoma Research

Background:

• Metastatic renal cancer treatment has evolved with molecular targeted drugs (MTDs) and immunotherapy.
• Sequential treatment strategies require real-world efficacy data.

Purpose of the Study:

• To evaluate the real-world effectiveness of sequential nivolumab in metastatic renal cancer patients.
• To identify factors influencing survival outcomes after first-line molecular targeted therapy.

Main Methods:

• Retrospective analysis of metastatic renal cancer patients treated between 2014-2016 and 2017-2020.
• Comparison of overall survival (OS) between patient groups based on treatment timing and sequential nivolumab use.
• Univariate analysis to identify prognostic factors.

Main Results:

• The 2017-2020 group showed significantly longer mean overall survival (44.0 months) compared to the 2014-2016 group (8.5 months).
• Nivolumab treatment was a significant positive prognostic factor (P = .0021).
• Patients receiving nivolumab as second-line therapy had a higher 5-year survival rate (70% vs 32%).

Conclusions:

• Sequential nivolumab therapy, particularly with prompt switching after first-line molecular targeted drugs, is associated with markedly prolonged outcomes.
• The 2017 guideline update appears to correlate with improved patient outcomes in metastatic renal cancer.